More than 16,000 dermatology trials were completed, ongoing, or planned by the end of 2025, with the Asia-Pacific region experiencing a nearly five-fold increase over the past decade. The field now accounts for around 8,000 trials in Asia-Pacific alone, matching North America and Europe combined.
The FDA approved Zycubo (copper histidinate) on January 13, 2026, as the first treatment for Menkes disease in pediatric patients, following resolution of manufacturing compliance concerns that led to an initial rejection in September 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07681583 |
Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score |
RECRUITING | |
| NCT07454122 |
CD5CAR-NK Cells for Refractory Invasive Mold Disease |
NOT_YET_RECRUITING | PHASE1 |
| NCT07238114 |
Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors |
ACTIVE_NOT_RECRUITING | |
| NCT07143409 |
Fungal Vascular Graft Infections, French Multicenter Retrospective Study |
NOT_YET_RECRUITING | |
| NCT07080359 |
Isavuconazole in Critically Ill Patients: Efficacy and Safety |
NOT_YET_RECRUITING | |
| NCT06774144 |
Rezafungin Prophylaxis in Liver Transplant |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT06582186 |
Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm |
NOT_YET_RECRUITING | PHASE4 |
| NCT06510699 |
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial |
RECRUITING | PHASE2 |
| NCT06417983 |
Topical Application of Essential Oils to Treat Onchomycosis |
NOT_YET_RECRUITING | |
| NCT06025682 |
Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO |
RECRUITING |
